ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML
A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.
Related Articles
The OncFive: Top Oncology Articles for the Week of 4/20
Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.
Advancing Brain Metastases Research and Mentorship in Breast Oncology: With D. Ross Camidge, MD, PhD; Nancy U. Lin, MD
Drs Camidge and Lin discussed Dr Lin’s work with brain metastases and her role in developing targeted therapies for breast cancer.
Dr Boffa on Factors Informing Early-Stage Esophageal Cancer Management
Daniel Boffa, MD, discusses the choice between definitive surgery vs definitive chemoradiotherapy for patients with early-stage esophageal carcinoma.
Dr Heymach on the Efficacy of Zongertinib in Previously Treated HER2-Mutant NSCLC
John V. Heymach, MD, PhD, discusses the activity of zongertinib in patients with previously treated advanced HER2-mutant NSCLC.
How Mirvetuximab Soravtansine Has Impacted Clinical Management of Ovarian Cancer
Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Dr. Wojciech Jurczak presents first disclosure results from the EPCORE DLBCL-3 trial, demonstrating that fixed-duration subcutaneous epcoritamab monotherapy achieves high response rates with a manageable…
Adjuvant Aumolertinib Boost DFS in Stage II-IIIB, EGFR-Mutated NSCLC
Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.
Adjuvant Trifluridine/Tipiracil Benefit is Limited to Select Subgroups in MRD+ CRC
Trifluridine/tipiracil showed a favorable safety profile and numerically improved DFS vs placebo in MRD-positive CRC.
Subgroup Analysis Shows No Key Differences Between High-Grade Recurrence, Cancer Progression Outcomes in BCG-Unresponsive NMIBC
Among 3 subgroups of patients with BCG-unresponsive NMIBC, no significant clinical differences were identified regarding rates of high-grade recurrence.
Adagrasib Yields Early Efficacy in STK11- and KRAS G12C–Mutant NSCLC
First-line adagrasib monotherapy demonstrated preliminary efficacy and tolerability in patients with SK11- and KRAS G12C–mutant NSCLC.